16 April 2014, 10:20 am
Adding pegylated interferon to entecavir (Baraclude) led to greater hepatitis B virus (HBV) viral load decline and higher likelihood of serological response in people with HBeAg-positive chronic hepatitis B, as did added interferon after long-term nucleoside therapy, but adding interferon after only a short course of antivirals did not improve response, according to a set

15 April 2014, 8:10 am
The largest study of new direct-acting antivirals yet conducted in people with hepatitis C genotype 1 who have compensated cirrhosis has shown that it is possible to cure between 92 and 96% of people with cirrhosis, regardless of previous treatment history, within 12 to 24 weeks, according to results of the TURQUOISE-II study presented

14 April 2014, 4:40 pm
A combination of two direct-acting antivirals developed by AbbVie cured 100% of previously untreated patients with hepatitis C genotype 4 infection when used with ribavirin, Christophe Hézode reported on Friday at the 49th Annual Meeting of the European Association for the Study of the Liver (EASL) in London. Genotype 4 hepatitis C virus (HCV)

14 April 2014, 10:30 am
A co-formulation of sofosbuvir and ledipasvir taken for as little as eight to twelve weeks produced high sustained response rates across the board for participants in the phase 3 ION trials, including people with genotype 1 hepatitis C virus (HCV) starting treatment for the first time, prior non-responders and people with liver cirrhosis, according

14 April 2014, 10:20 am
A 12-week oral regimen of sofosbuvir (Sovaldi) plus simeprevir (Olysio) without pegylated interferon or ribavirin led to sustained virological response in 93% of people with genotype 1 hepatitis C virus (HCV) with either absent to moderate liver fibrosis or with advanced fibrosis or cirrhosis, according to data from the COSMOS trial presented last week

1 2

    • No upcoming events
  • View All Add your news